CorMedix (CRMD) highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services, CMS, and the Center for Medicare and Medicaid Innovation, CMMI, released important policy updates that will broaden the access of Medicare patients managing End Stage Renal Disease, ESRD, and on dialysis to innovative new therapies. Joe Todisco, CorMedix CEO, commented, “CorMedix applauds CMS for making a patient-centered policy change that will align provider incentives with patient care and broaden access to innovation. I am appreciative of the industry stakeholders, patient advocacy organizations, and CorMedix team members that worked closely with CMS to enact this change for the benefit of patient access. This important change will better allow providers to more easily protocolize a product like DefenCath across clinics and patient payor segments system-wide.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRMD:
- CorMedix Approves Key Governance and Incentive Changes
- CorMedix Inc. Reports Q3 2024 Financial Results
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- CorMedix reports Q3 EPS (5c), consensus (10c)
- CRMD Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
